Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 for Moderate to Severe Alopecia Areata (Phase 3, France)
2020-002704-40Phase 3Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deuruxolitinib in alopecia areata (3 arms), sponsored by Concert Pharmaceuticals. Started Oct 2020; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2020-002704-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002704-40.